Targeted
Immuno-Oncology Platform

Targeted Immuno-Oncology Platform

Therapy Indication Partners Discovery Pre-Clinical Phase I Phase II
how long does it take to viagra to work c. wright mills essay on intellectual craftsmanship humanistic design thesis qual o valor do remedio cialis como comprar viagra en la farmacia https://www.aestheticscienceinstitute.edu/medical/minimum-amount-of-viagra/100/ best american essays 2008 cracking open co algesic contre indication cialis law 531 legal forms of business paper go see url viagra faz mal pra quem nao precisa https://shilohchristian.org/buy/brulure-caustique-classification-essay/54/ how to write a good application form order levitra from canada summary of an essay on man by alexander pope cheap masters personal essay topic essay about my school days see url esiste un cialis generico cialis and lupus compare and contast essay helper creative writing belonging go here source site source url does celebrex elevate blood pressure https://energy-analytics-institute.org/freefeatures/cheap-descriptive-essay-writers-services/56/ thesis on fluid mechanics enter site http://hyperbaricnurses.org/14671-viagra-no-prescrition/ go here ACT-901
(AFP + paclitaxel)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-902
(AFP + thapsigargin)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration University Health Network
 
ACT-903
(AFP + linker + maytansine)
Targeted Immuno-Oncology
Solid and liquid tumors
Collaboration Abzena
 

Lead Assets

ACT-901 (AFP + paclitaxel)

  • Paclitaxel is a widely used generic chemotherapy
  • ACT-901 combines highly targeted transporter protein AFP with a paclitaxel payload

ACT-902 (AFP + thapsigargin)

  • Thapsigargin is a potent generic chemotherapy drug equally effective against aggressive and slow growing tumors
  • ACT-902 combines highly targeted transporter protein AFP with a thapsigargin payload

ACT-903 (AFP + linker + maytansine)

  • Maytansine is a potent microtubule-targeted chemotherapy drug that induces mitotic arrest and kills tumor cells
  • ACT-903 combines highly targeted transporter protein AFP with a maytansine payload using cleavable linker

Targeted Immuno-Oncology

Alpha Fetoprotein (AFP)

  • AFP a shuttle protein that targets AFP receptors on cancer cells
  • Majority of solid and liquid cancer cells (>80%) have AFP receptors
  • Healthy cells do not have AFP receptors
  • Payload is delivered selectively to cancer cells

Preparation of ACT-901 (Taxol Solubilization)

Benefits

  • Formulation combining two well-known compounds
  • Currently in development for ovarian cancer / testicular germ cell tumors – Orphan Drug / Breakthrough Therapy
  • Will expand to other major indications
  • Overcomes chemotherapy drug resistance as delivery bypasses membrane pumps
  • AFP is non-immunogenic in humans - demonstrated safety in over 300 patients (as safe as placebo)
  • Frequency of treatment driven by efficacy, not toxicity avoidance
  • Treatment expected to minimize pain, suffering and healthcare cost

Target Product Profile

  • Significantly less toxicity than targeted and non-targeted chemotherapy
  • Improved efficacy compared with chemotherapy
  • Not necessary to preselect patients for expression of the AFP receptor, because receptors are expressed in most cancers (solid and liquid), but are absent in normal tissues